mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation

J Hepatol. 2011 Feb;54(2):396-8. doi: 10.1016/j.jhep.2010.08.038. Epub 2010 Nov 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzenesulfonates / administration & dosage*
  • Carcinoma, Hepatocellular / therapy*
  • Combined Modality Therapy
  • Everolimus
  • Humans
  • Liver Neoplasms / therapy*
  • Liver Transplantation*
  • Neoplasm Recurrence, Local / therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / administration & dosage*
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use
  • Sorafenib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Everolimus
  • Sorafenib
  • TOR Serine-Threonine Kinases
  • Sirolimus